Thumbnail Image
Publication

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Evens, A. M.
; 
Connors, J. M.
; 
Younes, A.
; 
Ansell, S. M.
; 
Kim, W. S.
; ; 
Feldman, T.
; 
Tuscano, J.
; 
Savage, K. J.
; 
Oki, Y.
... show 9 more
Citations
Altmetric:
Abstract
Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.
Authors
Evens, A. M.
Connors, J. M.
Younes, A.
Ansell, S. M.
Kim, W. S.
Radford, John A
Feldman, T.
Tuscano, J.
Savage, K. J.
Oki, Y.
Grigg, A.
Pocock, C.
Dlugosz-Danecka, M.
Fenton, K.
Forero-Torres, A.
Liu, R.
Jolin, H.
Gautam, A
Gallamini, A.
Affiliation
Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Description
Date
2021
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
From UNPAYWALL
Adobe PDF, 1.25 MB
Keywords
Type
Article
Citation
Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. haematol . 2021 Jun 24.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/624232
Embedded videos